INFINITT Healthcare Valuation
Is A071200 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A071200 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A071200 (₩4525) is trading below our estimate of fair value (₩10619)
Significantly Below Fair Value: A071200 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A071200?
Key metric: As A071200 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is A071200's PE Ratio? | |
|---|---|
| PE Ratio | 3.7x |
| Earnings | ₩29.86b |
| Market Cap | ₩110.30b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A071200's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16x | ||
A099750 ezCaretech | 36.5x | n/a | ₩111.2b |
A032850 BIT Computer | 12.7x | n/a | ₩78.7b |
A100700 Sewoon Medical | 8x | n/a | ₩113.0b |
A065510 Huvitz | 6.9x | n/a | ₩85.9b |
A071200 INFINITT Healthcare | 3.7x | n/a | ₩110.3b |
Price-To-Earnings vs Peers: A071200 is good value based on its Price-To-Earnings Ratio (3.7x) compared to the peer average (16x).
Price to Earnings Ratio vs Industry
How does A071200's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?
Price-To-Earnings vs Industry: A071200 is good value based on its Price-To-Earnings Ratio (3.7x) compared to the Asian Healthcare Services industry average (23.4x).
Price to Earnings Ratio vs Fair Ratio
What is A071200's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 3.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A071200's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Access Bio
₩189.3b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,600.00
7D
0.2%
1Y
-38.9%
Wonbiogen
₩44.8b
Develops and sells medical equipment in South Korea.
A307280
₩1,262.00
7D
1.9%
1Y
-18.7%
Boditech Med
₩356.7b
Offers instruments and diagnostic reagents in South Korea and internationally.
A206640
₩16,230.00
7D
1.3%
1Y
-5.0%